In this trial, patients taking ZEPBOUND in combination with an insulin secretagogue (e.g., sulfonylurea) had increased risk of hypoglycemia (10.3%) compared to ZEPBOUND-treated patients not taking a sulfonylurea (2.1%)
Overall tolerability of the treatment was good, with the most common side effect being nausea, particularly during treatment initiation or dose adjustments, while diarrhea was reported by 5% of patients, which was dose-dependent and easily managed
Klose, M., Huynh, K., Krogsgaard, K., Drejer, J., Byberg, S., Madsbad, S., Magkos, F., Aharaz, A., Edsberg, B., Tfelt, J., & Astrup, A
Retatrutide arrives in a lyophilized state
Semaglutide and Lifestyle Changes While Semaglutide can significantly aid in weight loss, its most effective when combined with lifestyle changes
Continue reading How much does semaglutide cost